Cargando…

Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience

Background and objectives: Hodgkin lymphoma (HL) is characterized by the presence of malignant Reed Sternberg cells. Although the current curability rate in patients with HL has increased, up to 30% of those in the advanced stages and 5% to 10% of those in limited stages of the disease, relapse. Acc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Potre, Ovidiu, Pescaru, Monica, Sima, Alexandra, Ionita, Ioana, Tudor, Raluca, Borsi, Ema, Samfireag, Miruna, Potre, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540813/ https://www.ncbi.nlm.nih.gov/pubmed/34684063 http://dx.doi.org/10.3390/medicina57101026

Ejemplares similares

High Carbohydrate Diet Is Associated with Severe Clinical Indicators, but Not with Nutrition Knowledge Score in Patients with Multiple Myeloma
por: Borsi, Ema, et al.
Publicado: (2021)

A Systematic Review Assessing the Impact of Vitamin D Levels on Adult Patients with Lymphoid Malignancies
por: Potre, Cristina, et al.
Publicado: (2023)

Approach to Thrombophilia in Pregnancy—A Narrative Review
por: Samfireag, Miruna, et al.
Publicado: (2022)

Assessment of the Particularities of Thrombophilia in the Management of Pregnant Women in the Western Part of Romania
por: Samfireag, Miruna, et al.
Publicado: (2023)

Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients
por: Potre, Cristina, et al.
Publicado: (2022)

Maternal and Newborn Characteristics—A Comparison between Healthy and Thrombophilic Pregnancy
por: Samfireag, Miruna, et al.
Publicado: (2023)

Whole-body diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient values as prognostic factors in multiple myeloma
por: Costachescu, Dan, et al.
Publicado: (2021)

Survival Analysis of Patients with Inflammatory Breast Cancer in Relation to Clinical and Histopathological Characteristics
por: Preda, Marius, et al.
Publicado: (2020)

Additional factors to corelate with a more than 30% NIHSS score improvement in patients 7 days after fibrinolytic and/or endovascular treatment for ischemic stroke
por: Tudor, Raluca, et al.
Publicado: (2020)

Validation and cross-cultural adaptation of the depression Patient’s Health Questionnaire – 9 in the Romanian population of patients with Type 2 Diabetes Mellitus
por: Lupascu, Nicoleta, et al.
Publicado: (2019)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
por: Casadei, Beatrice, et al.
Publicado: (2021)

P1074: PRIMARY REFRACTORY HODGKIN’S LYMPHOMA: A MOROCCAN MONOCENTRIC RETROSPECTIVE STUDY
por: Ababou, M., et al.
Publicado: (2022)

The Impact Of Hyperuricemia On Cardiometabolic Risk Factors In Patients With Diabetes Mellitus: A Cross-Sectional Study
por: Gaita, Laura, et al.
Publicado: (2019)

Instrument for Assessing Patients’ Desirability, Acceptability, and Adherence to Telemedicine in Diabetes: Development, Validity, and Reliability
por: Patrascu, Raul, et al.
Publicado: (2021)

Predictors of Epicardial Fat Volume Decrease after Dapagliflozin Treatment in Patients with Type 2 Diabetes
por: Braha, Adina, et al.
Publicado: (2021)

Factors Influencing the Desirability, Acceptability, and Adherence of Patients with Diabetes to Telemedicine
por: Patrascu, Raul, et al.
Publicado: (2022)

Mediastinal Choriocarcinoma Masquerading as Relapsed Hodgkin Lymphoma
por: Lam, Selay, et al.
Publicado: (2011)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Non-Hodgkin lymphoma with relapses in the lacrimal glands
por: Couceiro, Rita, et al.
Publicado: (2015)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

Non hepatitis jaundice - adverse reaction to rifampicin
por: Laza, Ruxandra, et al.
Publicado: (2014)

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas
por: Rindone, Giovanni, et al.
Publicado: (2022)

Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas
por: Gaudio, Francesco, et al.
Publicado: (2011)

Paraspinal mass as a presentation in relapsed Hodgkin lymphoma
por: Dua, Vikas, et al.
Publicado: (2013)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Tumor-Infiltrating Macrophages in Post-Transplant, Relapsed Classical Hodgkin Lymphoma Are Donor-Derived
por: Crane, Genevieve M., et al.
Publicado: (2016)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
por: Weide, Rudolf
Publicado: (2008)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
por: Hallam, Simon
Publicado: (2018)

Generalized granuloma annulare heralding relapse of non-Hodgkin lymphoma
por: King, Sarah A., et al.
Publicado: (2020)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Proteomic Profiles and Biological Processes of Relapsed vs. Non-Relapsed Pediatric Hodgkin Lymphoma
por: Repetto, Ombretta, et al.
Publicado: (2020)

The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
por: Beard, S M, et al.
Publicado: (2000)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
por: Di Folca, S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7i5klk3csc1dre92d64gh7ppq3